| CAS: | 1233332-14-3 | |||
| 分子式: | C27H29ClN2O3 | |||
| 分子量: | 464.98 | |||
| 中文名称: |
| |||
| 英文名称: |
|
| 货号 | 品牌 | 产品名称 | 规格 | 包装、参考价格 | 详情 | ||||||||||||||||||||||||||||
| R727699 | MACKLIN | (3'-(((R)-1-(4-氯-3-甲基苯基)乙基)氨基)-3,5-二甲基-[1,1'-联苯]-4-羰基)-L-丙氨酸 | 99% | 407元/1mg; 1420元/5mg; 2130元/10mg; | 展开 | ||||||||||||||||||||||||||||
储存:-20°C, 干燥 | |||||||||||||||||||||||||||||||||
| SML2099 | Sigma-Aldrich | NIBR-0213 | ≥98% (HPLC) | 1649.92元/5 MG; 5909.96元/25 MG; | 展开 | ||||||||||||||||||||||||||||
产品说明 应用 NIBR-0213 may be used as a selective sphingosine-1-phosphate receptor 1 (S1P1) antagonist to assess S1P-mediated nuclear factor kappa B (NF-κB)-p65 nuclear translocation in human induced astrocytes. 生化/生理作用 NIBR-0213 is an orally active, potent and S1P1-selective sphingosine 1-phosphate (S1P) receptor antagonist that blocks S1P1-selective ligand AUY954-induced Ca2+ mobilization (IC50 = 2.5 nM using human S1P1-transfected HeLa cells; IC50 >10 μM with human S1P2, S1P3, or S1P4 transfectants) and S1P-induced GTPγS recruitment (IC50 = 2.0/2.3/8.5 nM using membrane from human/murine/rat S1P1-transfected CHO cells; IC50 >10 μM with membrane from human S1P5 transfectant). NIBR-0213 induces long-lasting peripheral blood lymphocyte reduction in rats (EDmax = 1 mg/kg, ED50 = 0.2 mg/kg; p.o.) and exhibits therapeutic efficacy (30 mg/kg p.o; BID) in experimental autoimmune encephalomyelitis (EAE), a murine model of multiple sclerosis (MS), with no adverse effects to the animals. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||